Quest Diagnostics (DGX) Tops Q2 EPS by 12c; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts DGX Hot Sheet
Join SI Premium – FREE
Quest Diagnostics (NYSE: DGX) reported Q2 EPS of $2.36, $0.12 better than the analyst estimate of $2.24. Revenue for the quarter came in at $2.45 billion versus the consensus estimate of $2.32 billion.
GUIDANCE:
Quest Diagnostics sees FY2022 EPS of $9.55-$9.95, versus the consensus of $9.33.
For earnings history and earnings-related data on Quest Diagnostics (DGX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance
- Reynolds Consumer Products Inc. (REYN) Tops Q3 EPS by 1c, Beats on Revenue; Offers FY26 EPS Guidance
- Peabody Energy (BTU) Misses Q3 EPS by 28c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
